Actinium Pharmaceuticals, Inc.
ATNMHealthcare|Biotechnology|US
$1.43
+0.13 (+10.00%)
DCF Value
$1.48
Tangible Book / Share
$0.97
Graham Number
$2.80
Cash / Share
$1.16
Financials
Financial Snapshot
Market Cap
$45.0M
Enterprise Value
$9.8M
Revenue (TTM)
$35.1M
Net Income (TTM)
$11.3M
Cash & Investments
$36.5M
Net Cash
$35.1M
Free Cash Flow (TTM)
-$23.2M
Operating CF (TTM)
-$22.7M
Debt/Equity
0.04
Cash Runway & Burn Rate
Cash on Hand
$36.5M
Quarterly Burn
$5.7M
Monthly Burn
$1.9M
Est. Runway
~6.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $20.5M | $17.4M | $13.7M | $9.3M | $63.6M | $77.8M | $108.9M | $76.7M | $72.9M | $48.0M | $36.5M | |
| Operating Cash Flow | -$20.8M | -$21.6M | -$20.6M | -$21.5M | -$21.6M | -$20.9M | $8.6M | -$47.3M | -$33.1M | -$24.6M | -$22.7M | |
| Free Cash Flow | -$20.8M | -$21.6M | -$20.7M | -$21.5M | -$21.9M | -$21.0M | $8.3M | -$47.5M | -$33.1M | -$24.7M | -$23.2M | |
| Capital Expenditure | -$60.0K | -$24.7K | -$96.1K | -$63.9K | -$253.0K | -$133.0K | -$366.0K | -$153.0K | -$11.0K | -$104.0K | -$584.0K | |
| Financing Cash Flow | $15.8M | $18.8M | $17.0M | $17.1M | $76.2M | $35.2M | $23.1M | $14.9M | $29.3M | -$217.0K | -$217.0K |
R&D Spending
R&D (TTM)
$18.7M
R&D Intensity
53.4%
R&D Growth vs Prior
-11.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $1.0M | $81.0K | $0.00 | $90.0K | $35.1M | |
| R&D Expense | $17.5M | $17.7M | $17.1M | $16.5M | $16.1M | $17.5M | $23.1M | $38.7M | $30.0M | $21.1M | $18.7M | |
| R&D % of Revenue | — | — | — | — | — | 1530.3% | 2246.1% | 47740.7% | — | 23471.1% | 53.4% | |
| SG&A | $9.3M | $9.2M | $6.7M | $5.1M | $6.3M | $8.1M | $12.0M | $13.3M | $12.1M | $15.2M | $7.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $1.0M | $81.0K | $0.00 | $90.0K | $35.1M | |
| Cost of Revenue | $77.5K | $55.9K | $50.7K | $420.1K | $447.0K | $524.0K | $0.00 | $0.00 | $811.0K | $0.00 | -$395.0K | |
| Gross Profit | -$77.5K | -$55.9K | -$50.7K | -$420.1K | -$447.0K | $620.0K | $1.0M | $81.0K | -$811.0K | $90.0K | $35.5M | |
| R&D | $17.5M | $17.7M | $17.1M | $16.5M | $16.1M | $17.5M | $23.1M | $38.7M | $30.0M | $21.1M | $18.7M | |
| SG&A | $9.3M | $9.2M | $6.7M | $5.1M | $6.3M | $8.1M | $12.0M | $13.3M | $12.1M | $15.2M | $7.4M | |
| Operating Income | -$26.8M | -$26.9M | -$23.8M | -$22.1M | -$22.4M | -$25.0M | -$34.1M | -$51.9M | -$42.1M | -$36.2M | $9.6M | |
| Interest Expense | $5.0K | $5.4K | $173.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$24.3M | -$26.6M | -$23.7M | -$21.9M | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M | $11.3M | |
| Net Income | -$24.3M | -$26.6M | -$23.7M | -$21.9M | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M | $11.3M | |
| EPS (Diluted) | -15.06 | -11.96 | -6.69 | -4.37 | -1.83 | -1.20 | -1.37 | -1.83 | -1.27 | -1.09 | 0.36 | |
| EBITDA | -$26.8M | -$26.9M | -$23.8M | -$21.5M | -$21.8M | -$24.3M | -$32.3M | -$48.0M | -$37.4M | -$33.1M | $12.2M | |
| Shares Out. (M) | 1.61 | 2.23 | 3.53 | 4.98 | 12.13 | 20.57 | 24.14 | 26.60 | 30.07 | 31.20 | 31.41 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.5M | $17.4M | $13.7M | $9.3M | $63.6M | $77.8M | $108.9M | $76.7M | $72.9M | $48.0M | $36.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $22.4M | $17.8M | $14.3M | $10.1M | $64.9M | $79.7M | $110.9M | $78.3M | $74.5M | $49.4M | $37.7M | |
| Total Assets | $22.5M | $18.3M | $14.9M | $11.7M | $66.4M | $80.4M | $114.2M | $81.4M | $76.9M | $51.8M | $40.2M | |
| Total Current Liabilities | $4.5M | $4.7M | $6.1M | $5.3M | $4.8M | $6.8M | $10.6M | $8.5M | $8.1M | $8.0M | $9.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $4.5M | $4.7M | $6.1M | $6.0M | $5.1M | $6.8M | $47.7M | $45.1M | $44.1M | $43.9M | $9.9M | |
| Stockholders' Equity | $18.0M | $13.7M | $8.8M | $5.6M | $61.3M | $73.5M | $66.5M | $36.4M | $32.8M | $7.8M | $30.3M | |
| Retained Earnings | -$136.6M | -$163.2M | -$186.9M | -$208.8M | -$231.0M | -$255.7M | -$288.8M | -$337.6M | -$375.8M | -$409.7M | -$387.3M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.8M | -$21.6M | -$20.6M | -$21.5M | -$21.6M | -$20.9M | $8.6M | -$47.3M | -$33.1M | -$24.6M | -$22.7M | |
| Capital Expenditure | -$60.0K | -$24.7K | -$96.1K | -$63.9K | -$253.0K | -$133.0K | -$366.0K | -$153.0K | -$11.0K | -$104.0K | -$584.0K | |
| Free Cash Flow | -$20.8M | -$21.6M | -$20.7M | -$21.5M | -$21.9M | -$21.0M | $8.3M | -$47.5M | -$33.1M | -$24.7M | -$23.2M | |
| Investing Cash Flow | -$109.8K | -$380.9K | -$96.1K | -$63.9K | -$253.0K | -$133.0K | -$366.0K | -$153.0K | -$11.0K | -$104.0K | -$584.0K | |
| Financing Cash Flow | $15.8M | $18.8M | $17.0M | $17.1M | $76.2M | $35.2M | $23.1M | $14.9M | $29.3M | -$217.0K | -$217.0K | |
| Issuance of Stock | $16.0M | $18.8M | $17.0M | $15.9M | $76.6M | $35.3M | $23.2M | $14.9M | $29.3M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$207.0K | -$207.0K | |
| Net Debt Issuance | -$265.7K | $0.00 | $0.00 | -$322.0K | -$460.0K | -$85.0K | -$49.0K | -$4.0K | -$9.0K | -$10.0K | -$10.0K | |
| Stock Based Comp. | $4.3M | $3.5M | $1.8M | $1.3M | $1.3M | $1.7M | $2.8M | $3.8M | $5.3M | $9.2M | $237.0K | |
| Net Change in Cash | -$5.1M | -$3.1M | -$3.7M | -$4.4M | $54.3M | $14.2M | $31.4M | -$32.6M | -$3.8M | -$24.9M | -$23.4M |
Dilution Tracker
Shares outstanding grew 157.1% over 5 years — significant dilution
Shares Outstanding
31M
5-Year Share Growth
+157.1%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.61 | 2.23 | 3.53 | 4.98 | 12.13 | 20.57 | 24.14 | 26.60 | 30.07 | 31.20 | 31.41 | |
| Change vs Prior % | — | 37.8% | 58.9% | 40.8% | 143.9% | 69.5% | 17.4% | 10.2% | 13.0% | 3.7% | 0.7% | |
| Stock Issuance | $16.0M | $18.8M | $17.0M | $15.9M | $76.6M | $35.3M | $23.2M | $14.9M | $29.3M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$207.0K | -$207.0K | |
| Stock Based Comp. | $4.3M | $3.5M | $1.8M | $1.3M | $1.3M | $1.7M | $2.8M | $3.8M | $5.3M | $9.2M | $237.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | 54.2% | 100.0% | 100.0% | — | 100.0% | 101.1% | |
| Operating Margin % | — | — | — | — | — | -2182.2% | -3311.1% | -64098.8% | — | -40274.4% | 27.2% | |
| Net Margin % | — | — | — | — | — | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% | 32.2% | |
| EBITDA Margin % | — | — | — | — | — | -2119.8% | -3137.7% | -59293.8% | — | -36740.0% | 34.7% | |
| FCF Margin % | — | — | — | — | — | -1835.6% | 803.7% | -58627.2% | — | -27426.7% | -66.2% | |
| ROE % | -135.1% | -194.6% | -268.4% | -388.0% | -36.2% | -33.7% | -49.7% | -134.2% | -116.7% | -432.6% | 83.4% | |
| ROA % | -108.0% | -145.1% | -158.9% | -187.6% | -33.5% | -30.8% | -28.9% | -59.9% | -49.7% | -65.5% | 28.2% | |
| ROIC % | -149.1% | -196.8% | -262.5% | -312.1% | -36.1% | -33.8% | -32.8% | -70.6% | -60.8% | -81.4% | 30.2% | |
| R&D / Revenue % | — | — | — | — | — | 1530.3% | 2246.1% | 47740.7% | — | 23471.1% | 53.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -10.0% | -92.1% | -100.0% | 0.0% | |
| Gross Profit | -45.0% | 27.8% | 9.3% | -728.2% | -6.4% | 238.7% | 66.1% | -92.1% | -1101.2% | 111.1% | |
| Operating Income | -8.1% | -0.2% | 11.5% | 7.4% | -1.5% | -11.5% | -36.6% | -52.2% | 18.9% | 13.9% | |
| Net Income | -15.7% | -9.4% | 11.1% | 7.4% | -1.4% | -11.5% | -33.3% | -47.9% | 21.7% | 11.4% | |
| EPS (Diluted) | 8.9% | 20.6% | 44.1% | 34.7% | 58.1% | 34.4% | -14.2% | -33.6% | 30.6% | 14.2% | |
| Operating Cash Flow | -12.1% | -3.7% | 4.6% | -4.3% | -0.7% | 3.5% | 141.4% | -647.6% | 30.1% | 25.7% | |
| Free Cash Flow | -12.1% | -3.5% | 4.2% | -4.2% | -1.6% | 4.0% | 139.4% | -673.7% | 30.3% | 25.4% | |
| R&D Expense | 31.5% | 1.1% | -3.4% | -3.2% | -2.8% | 8.8% | 32.1% | 67.1% | -22.3% | -29.7% | |
| SG&A Expense | -19.2% | -1.2% | -26.5% | -24.2% | 23.6% | 28.0% | 48.6% | 11.1% | -9.4% | 26.0% | |
| Total Assets | -15.3% | -18.6% | -18.8% | -21.6% | 468.9% | 21.1% | 42.1% | -28.7% | -5.6% | -32.7% | |
| Book Value / Share | -35.5% | -44.9% | -59.4% | -54.5% | 345.5% | -29.2% | -23.0% | -50.3% | -20.3% | -76.9% | |
| Debt | -100.0% | 0.0% | 0.0% | 443.9% | -48.3% | -58.0% | 732.6% | -18.1% | -25.6% | 7.7% | |
| Diluted Shares | 27.0% | 37.8% | 58.9% | 40.8% | 143.9% | 69.5% | 17.4% | 10.2% | 13.0% | 3.7% |
Valuation
P/E (TTM)3.97
P/S1.28
10Y Low / Med / High108.05 / 471.40 / 1668.50
P/B1.48
10Y Low / Med / High1.16 / 3.72 / 5.76
EV/EBITDA0.81
EV/Revenue0.28
10Y Low / Med / High40.29 / 146.39 / 747.95
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.48
Tangible Book / Share
$0.97
Net Current Assets / Share
$0.89
Graham Number
$2.80
Graham Net-Net
$0.85
Cash / Share
$1.16
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1.74 | -1.66 | -1.74 | -1.49 | -4.26 | -5.01 | -7.77 | -2.78 | -0.99 | -1.25 | 3.97 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 108.05 | 249.62 | 1668.50 | 0.00 | 471.40 | 1.28 | |
| P/B Ratio | 2.35 | 3.24 | 4.66 | 5.76 | 1.54 | 1.68 | 3.87 | 3.72 | 1.16 | 5.42 | 1.48 | |
| EV/EBITDA | -0.82 | -1.00 | -1.16 | -1.15 | -1.46 | -1.90 | -4.67 | -1.26 | 0.89 | 0.12 | 0.81 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.29 | 146.39 | 747.95 | 0.00 | -43.08 | 0.28 |
Analyst Estimates & Quality
Altman Z-Score
-8.11
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $35.0M | $19.4M | $1.9M |
| Net Income | $4.9M | -$17.5M | -$27.3M |
| EPS | $0.18 | $-0.57 | $-0.55 |
| # Analysts (EPS) | 2 | 2 | 4 |
Revenue Segments
By Product
| Segment | 2023 | 2025 |
|---|---|---|
| Other Revenue Member | $81.0K | $90.0K |